Role for expression of CD200 in multiparameter flow cytometric differential diagnosis of mature B-cell neoplasms

Reginald M. Gorczynski


This issue of the journal includes an important study by Sandes et al. (1), which explores whether inclusion of analysis of CD200 expression can contribute to improved classification of mature B cell neoplasms (MBN). Currently, the most frequent subgroupings used for classification purposes are (2,3): CD5+CD10− [(chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)]; CD5−CD10+ [Follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and Burkitt’s lymphoma]; and CD5−CD10− [marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma, and lymphomas with hairy/villous cells including splenic marginal zone lymphoma (SMZL), and hairy cell leukemia (HCL)].